Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE
Take your Radio, Podcasts and Music with you
